Both the American Cancer Society, in 2018, and the U.S. Preventive Services Task Force, in 2021, lowered their recommended starting age for average-risk colorectal cancer screening from 50 to 45 — a guideline change driven by a clearly documented and consistent trend in cancer registry data showing rising colorectal cancer incidence specifically among adults under 50, even as overall colorectal cancer rates in older adults have declined thanks to widespread screening.
The Underlying Epidemiological Trend Prompting the Change
SEER cancer registry data has shown a clear, sustained rise in colorectal cancer incidence among adults in their 20s, 30s, and 40s over recent decades, a trend that stands in contrast to declining rates in adults over 50 during the same period — a pattern researchers describe as a genuine generational shift rather than simply improved detection, since the rise has been documented consistently across multiple independent data sources and includes more advanced-stage diagnoses at younger ages, not just earlier detection of cancers that would have been found regardless.
The Cause of Rising Early-Onset Rates Remains an Active Research Question
Researchers have proposed multiple contributing factors for the early-onset trend, including rising obesity rates, dietary pattern shifts toward more processed food and red meat consumption, declining physical activity, and changes in the gut microbiome potentially linked to some of these same dietary and lifestyle shifts — but no single factor has been established as the definitive primary driver, and this remains one of the more actively studied open questions in colorectal cancer epidemiology.
Multiple Screening Modalities Are Available, Not Just Colonoscopy
Guidelines present several screening options rather than colonoscopy alone: colonoscopy every 10 years remains the most comprehensive option, allowing both detection and removal of precancerous polyps in the same procedure, while stool-based tests — including the fecal immunochemical test (FIT) annually or a stool DNA test every three years — offer a non-invasive alternative that, while requiring more frequent testing and not allowing simultaneous polyp removal, has documented mortality-reduction evidence when performed consistently on the recommended schedule. Guidelines emphasize that the best screening test is the one a patient will actually complete consistently, given that adherence varies considerably by test type and patient preference.
A Positive Stool-Based Test Still Requires Follow-Up Colonoscopy
An important and sometimes underappreciated point in the guideline structure is that a positive result on any stool-based screening test requires a follow-up diagnostic colonoscopy to evaluate the finding — the stool test identifies elevated risk or a possible finding, but colonoscopy remains necessary to actually visualize and, if needed, biopsy or remove any concerning tissue. Patients choosing a stool-based test for its convenience should understand this two-step pathway rather than viewing it as a complete substitute for ever needing a colonoscopy.
Family History and Symptoms Still Warrant Earlier, Individualized Screening
The lowered age-45 starting point applies specifically to average-risk individuals; patients with a family history of colorectal cancer or certain hereditary syndromes, or those presenting with concerning symptoms like rectal bleeding or unexplained changes in bowel habits at any age, warrant individualized, often earlier, evaluation rather than waiting for the standard average-risk screening age — a distinction that has taken on added importance given the rising early-onset trend making symptomatic younger patients less safe to dismiss without evaluation than guidelines calibrated to an earlier era's epidemiology would have suggested.
Conclusion
The lowered colorectal cancer screening age reflects genuine, well-documented epidemiological data on rising early-onset disease, even as the underlying cause of that generational shift remains under active investigation. Practices implementing expanded screening at the new age threshold rely on reliable diagnostic equipment and lab supplies to support both stool-based and procedural screening pathways.
